Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 9/20 | 1.00 |
| ▸ | HTR1A | P08908 | 8/20 | 1.00 |
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 6/20 | 0.78 |
| ▸ | HTR1D | P28221 | 11/20 | 0.74 |
| ▸ | MPO | P05164 | 1/20 | 0.68 |
| ▸ | HTR1B | P28222 | 7/20 | 0.67 |
| ▸ | HTR3E | A5X5Y0 | 3/20 | 0.65 |
| ▸ | HTR3B | O95264 | 3/20 | 0.65 |
| ▸ | HTR1E | P28566 | 3/20 | 0.65 |
| ▸ | HTR1F | P30939 | 3/20 | 0.65 |
| ▸ | HTR7 | P34969 | 3/20 | 0.65 |
| ▸ | HTR3A | P46098 | 3/20 | 0.65 |
| ▸ | HTR5A | P47898 | 3/20 | 0.65 |
| ▸ | HTR6 | P50406 | 3/20 | 0.65 |
| ▸ | HTR4 | Q13639 | 3/20 | 0.65 |
| ▸ | HTR3D | Q70Z44 | 3/20 | 0.65 |
| ▸ | HTR3C | Q8WXA8 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bufotenine SCHEMBL518028 | 1.00 | HTR2C (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| Bufotenine SCHEMBL5832731 | 0.93 | HTR1A (0.86) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL31041081 | 0.88 | HTR2C (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL21846788 | 0.87 | HTR1D (0.77) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL23069145 | 0.85 | HTR1D (0.78) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL21333441 | 0.85 | HTR2C (0.74) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| Bufotenine SCHEMBL31098272 | 0.85 | HTR2C (0.74) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL23069123 | 0.85 | HTR1D (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL23069161 | 0.84 | HTR2C (0.72) | HTR2CHTR1AHTR2ASLC6A4HTR2B | |
| SCHEMBL8891077 | 0.84 | HTR1D (1.00) | HTR2CHTR1AHTR2ASLC6A4HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | DRESDNER JR KARL P (US) | 2026-04-02 | — | — | US | claimed |
| WO-2025099725-A1 | CONJUGATES AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2025-05-15 | — | — | WO | claimed |
| EP-4547250-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | Terran Biosciences Inc. (US) | 2025-05-07 | — | — | EP | claimed |
| EP-4313030-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | Terran Biosciences, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2024006984-A1 | METHODS AND COMPOSITIONS RELATING TO CONTROLLING PSYCHEDELIC EFFECTS WITH SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2024-01-04 | — | — | WO | claimed |
| WO-2022212854-A1 | METHODS AND COMPOSITIONS RELATING TO PSYCHEDELICS AND SEROTONIN RECEPTOR MODULATORS | TERRAN BIOSCIENCES INC. (US) | 2022-10-06 | — | — | WO | claimed |
| CN-122005549-A | Application of indole alkali compound in preparation of medicine or skin care product for treating or preventing skin diseases | 南京效真生物科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | Natural MedTech Pty Ltd (AU) | 2025-11-06 | — | — | US | disclosed |
| EP-4640256-A2 | MIST INHALER DEVICES FOR THERAPEUTIC DELIVERY | Shaheen Innovations Holding Limited (AE) | 2025-10-29 | — | — | EP | disclosed |
| EP-4638757-A1 | METHODS FOR THE PRODUCTION OF TRYPTOPHAN DERIVATIVES | Natural Medtech Pty Ltd (AU) | 2025-10-29 | — | — | EP | disclosed |
| EP-4615444-A1 | TRYPTAMINE FORMULATIONS AND USES THEREOF | Natural Medtech Pty Ltd (AU) | 2025-09-17 | — | — | EP | disclosed |
| EP-4615414-A1 | ORALLY ADMINISTRABLE FORMULATION | Greenspoon, Allen (CA) | 2025-09-17 | — | — | EP | disclosed |
| EP-4608482-A1 | MULTI-CHAMBER MIST GENERATOR FOR GENERATING MIST INCLUDING A THERAPEUTIC | Shaheen Innovations Holding Limited (AE) | 2025-09-03 | — | — | EP | disclosed |
| CN-114727934-A | Wound debridement system | 雷杰尼斯有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2022115798-A2 | COMPOSITIONS AND METHODS FOR TREATING MIGRAINE | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115796-A1 | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS | WESANA HEALTH INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022099424-A1 | ENGINEERED MICROORGANISMS FOR PRODUCING SUBSTITUTED TRYPTAMINES | ALGAE-C INC. (CA) | 2022-05-19 | — | — | WO | disclosed |
| EP-3994458-A1 | ARYLALKYLAMINE, PYRROLE, INDOLE AND OPIATE DERIVATIVE CONCENTRATION DETERMINATION METHOD AND TEST KIT USING SAID METHOD | Blei, Felix (DE) | 2022-05-11 | — | — | EP | disclosed |
| WO-2022081631-A1 | GPCR SCREENING METHOD TO IDENTIFY NON-HALLUCINOGENIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-04-21 | — | — | WO | disclosed |
| CN-113956188-A | Synthesis method of N, N-dimethyl-5-methoxytryptamine | 河北维达康生物科技有限公司 | 2022-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260090957-A1 | Process for making aqueous therapeutic particle having stable exterior water clustering with nanosized thickness | QPCT, SLC38A7, QPCTL | HTR2C 1076/4885HTR1A 2572/4885HTR2A 2610/4885 |
| US-20250339403-A1 | Tryptamine Formulations and Uses Thereof | MAOA, MAOB, TPH1 | HTR2C 33/4885HTR1A 15/4885HTR2A 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.